LA HB918

Louisiana Department of Health must develop and maintain a "critical prescription drug list" of medications with substantial public interest in pricing transparency, updated at least every 3 years

Manufacturers of listed drugs must report production costs, R&D expenses (including publicly funded research), marketing/advertising costs, international pricing by country, and prices charged to Louisiana pharmacies and wholesalers

Department must submit annual reports to the legislature identifying drugs with "excessively high" costs compared to other states/countries and relative to development costs, with optional recommendations for lowering prices

Anyone marketing prescription drugs directly to healthcare providers must disclose wholesale acquisition costs, pricing history since U.S. market entry, and manufacturer information in all educational or marketing materials

Violations of reporting or disclosure requirements constitute prohibited practices under Louisiana's Unfair Trade Practices and Consumer Protection Law; manufacturer-reported data is confidential and exempt from public records disclosure